181 related articles for article (PubMed ID: 24595526)
1. Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa).
Fu M; Zhang W; Shan L; Song J; Shang D; Ying J; Zhao J
Virchows Arch; 2014 May; 464(5):575-81. PubMed ID: 24595526
[TBL] [Abstract][Full Text] [Related]
2. [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].
Gao J; Chen JQ; Zhang L; Liang ZY
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):652-6. PubMed ID: 23302304
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.
Borràs E; Jurado I; Hernan I; Gamundi MJ; Dias M; Martí I; Mañé B; Arcusa A; Agúndez JA; Blanca M; Carballo M
BMC Cancer; 2011 Sep; 11():406. PubMed ID: 21943394
[TBL] [Abstract][Full Text] [Related]
4. Molecular Characterization of KRAS, BRAF, and EGFR Genes in Cases with Prostatic Adenocarcinoma; Reporting Bioinformatics Description and Recurrent Mutations.
Salmaninejad A; Ghadami S; Dizaji MZ; Golchehre Z; Estiar MA; Zamani MR; Ebrahimzadeh-Vesal R; Nowroozi MR; Shakoori A
Clin Lab; 2015; 61(7):749-59. PubMed ID: 26299074
[TBL] [Abstract][Full Text] [Related]
5. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
Kosaka T; Yatabe Y; Onozato R; Kuwano H; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):22-9. PubMed ID: 19096302
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.
Fakhruddin N; Mahfouz R; Farhat F; Tfayli A; Abdelkhalik R; Jabbour M; Yehia L; Mahfoud Z; Zaatari G
Oncol Rep; 2014 Nov; 32(5):2223-9. PubMed ID: 25120214
[TBL] [Abstract][Full Text] [Related]
8. Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans.
Reinersman JM; Johnson ML; Riely GJ; Chitale DA; Nicastri AD; Soff GA; Schwartz AG; Sima CS; Ayalew G; Lau C; Zakowski MF; Rusch VW; Ladanyi M; Kris MG
J Thorac Oncol; 2011 Jan; 6(1):28-31. PubMed ID: 21107288
[TBL] [Abstract][Full Text] [Related]
9. Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas.
Gao B; Sun Y; Zhang J; Ren Y; Fang R; Han X; Shen L; Liu XY; Pao W; Chen H; Ji H
J Thorac Oncol; 2010 Aug; 5(8):1130-5. PubMed ID: 20559149
[TBL] [Abstract][Full Text] [Related]
10. Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?
Kim ST; Sung JS; Jo UH; Park KH; Shin SW; Kim YH
Med Oncol; 2013 Mar; 30(1):328. PubMed ID: 23307237
[TBL] [Abstract][Full Text] [Related]
11. [Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].
Sun LN; Luan HL; Zang FL; Wang M; Dong N; Guo Y; Sun BC; Zhan ZL
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):667-70. PubMed ID: 21122380
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status.
Wang J; Dong Y; Cai Y; Zhou L; Wu S; Liu G; Su D; Li X; Qin N; Nong J; Jia H; Zhang Q; Mu J; Zeng X; Zhang H; Zhang S; Zhang Z
J Cancer Res Clin Oncol; 2014 Mar; 140(3):453-60. PubMed ID: 24442099
[TBL] [Abstract][Full Text] [Related]
13. Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.
Xia N; An J; Jiang QQ; Li M; Tan J; Hu CP
Exp Lung Res; 2013 Oct; 39(8):328-35. PubMed ID: 23919423
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas.
Dacic S; Shuai Y; Yousem S; Ohori P; Nikiforova M
Mod Pathol; 2010 Feb; 23(2):159-68. PubMed ID: 19855375
[TBL] [Abstract][Full Text] [Related]
15. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.
Marotti JD; Schwab MC; McNulty NJ; Rigas JR; DeLong PA; Memoli VA; Tsongalis GJ; Padmanabhan V
Diagn Cytopathol; 2013 Jan; 41(1):15-21. PubMed ID: 21681971
[TBL] [Abstract][Full Text] [Related]
16. Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center.
D'Angelo SP; Park B; Azzoli CG; Kris MG; Rusch V; Ladanyi M; Zakowski MF
J Thorac Cardiovasc Surg; 2011 Feb; 141(2):476-80. PubMed ID: 20933246
[TBL] [Abstract][Full Text] [Related]
17. LKB1, TP16, EGFR, and KRAS somatic mutations in lung adenocarcinomas from a Chiba Prefecture, Japan cohort.
Suzuki Y; Oonishi T; Kudo T; Doi H
Drug Discov Ther; 2012 Feb; 6(1):24-30. PubMed ID: 22460425
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma.
Shibata T; Hanada S; Kokubu A; Matsuno Y; Asamura H; Ohta T; Sakamoto M; Hirohashi S
Cancer Sci; 2007 Jul; 98(7):985-91. PubMed ID: 17459062
[TBL] [Abstract][Full Text] [Related]
19. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas.
Sonobe M; Kobayashi M; Ishikawa M; Kikuchi R; Nakayama E; Takahashi T; Menju T; Takenaka K; Miyahara R; Huang CL; Okubo K; Bando T; Date H
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S347-54. PubMed ID: 21607772
[TBL] [Abstract][Full Text] [Related]
20. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]